141 related articles for article (PubMed ID: 2459306)
21. Taurine infused intrastriatally elevates, but intranigrally decreases striatal extracellular dopamine concentration in anaesthetised rats.
Ruotsalainen M; Heikkilä M; Lillsunde P; Seppälä T; Ahtee L
J Neural Transm (Vienna); 1996; 103(8-9):935-46. PubMed ID: 9013387
[TBL] [Abstract][Full Text] [Related]
22. Increased dopamine metabolism in rat striatum after infusions of substance P into the substantia nigra.
Waldmeier PC; Kam R; Stöcklin K
Brain Res; 1978 Dec; 159(1):223-7. PubMed ID: 728796
[No Abstract] [Full Text] [Related]
23. In vivo and in vitro actions of mammalian tachykinins.
Holzer-Petsche U; Schimek E; Amann R; Lembeck F
Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):130-5. PubMed ID: 2413373
[TBL] [Abstract][Full Text] [Related]
24. Rotatory behavior in rats by intranigral application of substance P and an eledoisin fragment.
Olpe HR; Koella WP
Brain Res; 1977 May; 126(3):576-9. PubMed ID: 861742
[No Abstract] [Full Text] [Related]
25. Inhibitory effect of intracranial injections of tachykinins on angiotensin-induced drinking in the cat.
Barocelli E; Chiavarini M; Impicciatore M; Massi M; de Caro G
Pharmacol Biochem Behav; 1988 Oct; 31(2):493-7. PubMed ID: 2469087
[TBL] [Abstract][Full Text] [Related]
26. Kainic acid-induced changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat.
Sperk G; Berger M; Hörtnagl H; Hornykiewicz O
Eur J Pharmacol; 1981 Sep; 74(4):279-86. PubMed ID: 6170518
[TBL] [Abstract][Full Text] [Related]
27. Tachykinins and related peptides in the substantia nigra and neostriatum.
Hökfelt T; Reid M; Herrera-Marschitz M; Ungerstedt U; Terenius L; Håkanson R; Feng DM; Folkers K
Ann N Y Acad Sci; 1991; 632():192-7. PubMed ID: 1719865
[No Abstract] [Full Text] [Related]
28. Effects of a fluorinated pyrimidinedione anti-cancer drug, 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FT), and related compounds on nigro-striatal dopaminergic neurons in the central nervous system.
Toide K; Unemi N; Segawa T
Arch Int Pharmacodyn Ther; 1985 Mar; 274(1):111-24. PubMed ID: 3925907
[TBL] [Abstract][Full Text] [Related]
29. Behavioral and biochemical assessment of time-related changes in globus pallidus and striatal dopamine induced by intranigrally administered neurotensin.
Napier TC; Gay DA; Hulebak KL; Breese GR
Peptides; 1985; 6(6):1057-68. PubMed ID: 3938838
[TBL] [Abstract][Full Text] [Related]
30. Effects of midazolam and flunitrazepam on the release of dopamine from rat striatum measured by in vivo microdialysis.
Takada K; Murai T; Kanayama T; Koshikawa N
Br J Anaesth; 1993 Feb; 70(2):181-5. PubMed ID: 8435263
[TBL] [Abstract][Full Text] [Related]
31. Effect of naloxone on morphine-induced changes in striatal dopamine metabolism and glutamate, ascorbic acid and uric acid release in freely moving rats.
Enrico P; Mura MA; Esposito G; Serra P; Migheli R; De Natale G; Desole MS; Miele M; Miele E
Brain Res; 1998 Jun; 797(1):94-102. PubMed ID: 9630540
[TBL] [Abstract][Full Text] [Related]
32. Mobilization of storage pool dopamine and late ipsilateral augmentation of striatal dopamine synthesis in the trained circling rat.
Bennett BA; Freed CR
J Neurochem; 1986 Aug; 47(2):472-6. PubMed ID: 3734789
[TBL] [Abstract][Full Text] [Related]
33. Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11.
Mattioli R; Schwarting RK; Huston JP
Neuroscience; 1992; 48(3):595-605. PubMed ID: 1376454
[TBL] [Abstract][Full Text] [Related]
34. Effects of Ca2+ antagonists on motor activity and the dopaminergic system in aged mice.
Kurosaki R; Akasaka M; Michimata M; Matsubara M; Imai Y; Araki T
Neurobiol Aging; 2003; 24(2):315-9. PubMed ID: 12498965
[TBL] [Abstract][Full Text] [Related]
35. Regulation of the synthesis and metabolism of striatal dopamine after disruption of nerve conduction in the medial forebrain bundle.
Commissiong JW; Slimovitch C; Toffano G
Br J Pharmacol; 1990 Apr; 99(4):741-9. PubMed ID: 2361171
[TBL] [Abstract][Full Text] [Related]
36. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain.
Costall B; Marsden CD; Naylor RJ; Pycock CJ
Brain Res; 1976 Dec; 118(1):87-113. PubMed ID: 990957
[TBL] [Abstract][Full Text] [Related]
37. Further evaluation of the mechanism by which amphetamine reduces striatal dopamine metabolism: a brain dialysis study.
Zetterström T; Sharp T; Ungerstedt U
Eur J Pharmacol; 1986 Dec; 132(1):1-9. PubMed ID: 3816961
[TBL] [Abstract][Full Text] [Related]
38. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
Xu K; Dluzen DE
J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
[TBL] [Abstract][Full Text] [Related]
39. Comparison of cardiovascular and bronchoconstrictor effects of substance P, substance K and other tachykinins.
Hua X; Lundberg JM; Theodorsson-Norheim E; Brodin E
Naunyn Schmiedebergs Arch Pharmacol; 1984 Dec; 328(2):196-201. PubMed ID: 6084817
[TBL] [Abstract][Full Text] [Related]
40. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Sirinathsinghji DJ; Whittington PE; Audsley AR
Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
